Ep. 46 - Dueling Rulings

This week on the FLATLINING Podcast, Ron and Matthew discuss two recent judicial decisions that contradict. A judge in Texas ruled that mifepristone, the drug used for over half of all abortions in the United States, should lose its approval status from the Food and Drug Administration (FDA). Then, on the same day, a judge in Washington ruled that the FDA needs to make the drug more widely available and stop some of its restrictions and warnings. What do these decisions mean for drug manufacturers and the independent practice of medicine? Plus: California backs off of Walgreens and CMS throws some pennies at hospitals. Subscribe to the FLATLINING Podcast on Apple Podcasts, Spotify, the iHeartRadio app, Amazon Music, Google Podcasts, Stitcher, Pandora, TuneIn, and Audible. Articles mentioned in this episode: 6 burning questions about how the FDA will handle conflicting abortion pill decisions - STATNewsom wanted California to cut ties with Walgreens. Then federal law got in way - Desert SunHospitals get a slight pay boost - Axios This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.flatlining.net